Andrew Timothy Kraftson, MD
Clinical Professor of Internal Medicine
Clinical Director, Post-Bariatric Program and Weight Navigation Program
Program Director, Endocrinology Fellowship
Medical School
Office:
University of Michigan
24 Frank Lloyd Wright Dr., Lobby C, Suite 1300
Ann Arbor, Michigan 48105
24 Frank Lloyd Wright Dr., Lobby C, Suite 1300
Ann Arbor, Michigan 48105
Available to mentor
Andrew Timothy Kraftson, MD
Clinical Professor
Manage Your Profile
About
Dr. Kraftson specializes in treating patients with excess weight/ obesity in addition to seeing patients with general endocrinologic conditions. He was inducted into the Clinical Excellence Society in 2021. He is the director of the Weight Navigation Program, director of the Post-Bariatric Endocrinology Clinic, and a participating physician in the Weight Management Program. His research focuses on understanding current treatment practices for patients with excess weight and obesity and seeking to improve and personalize that care. In addition to these interests, Dr. Kraftson is actively involved in medical education and is the Associate Program Director for the MEND Endocrinology Fellowship.
Center Memberships
-
Center MemberCaswell Diabetes Institute
Recent Publications
-
Blum D. 2026 Sep 24;Additional ScholarshipNew York Times Interview: GLP-1 Prescriptions for People With No Medical Need Are Climbing
-
Oshman L, Runyon A, Vicenzi Bal A, Arizaca-Dileo P, Sen A, Othman A, Gabison J, Rothberg A, Kraftson A, Griauzde DH, Fendrick AM. Obesity Pillars, 2026 Jul 20; 19 (September 2026):Journal ArticleA survey of primary care physicians' views on supporting patients who lose insurance coverage for Glucagon-Like Peptide-1-based drugs for weight management
-
Griauzde D, Turner CD, Othman A, Oshman L, Gabison J, Arizaca P, Henderson J, Beckius D, Lee JM, Stoll S, Herrera-Theut K, Richardson CR, Kullgren JT, Piatt GA, Heisler M, Kraftson A. 2026 Mar 25;Journal ArticleGLP-1 RA Use and Weight Loss Among Patients in a Weight Navigation Program Versus Primary Care: A Matched Cohort Study
-
Blum D. 2026 Mar 26;Additional ScholarshipNew York Times Interview: A New Concern About Weight Loss Drugs: What if They Work Too Well?
-
Khurram D, Kupkova K, Mesner LD, Kraftson AT, Farber CR, Clines GA. JCEM Case Rep, 2026 Sep 19; 3 (12): luaf239 - luaf239.Journal ArticleOsteoporosis Associated with SCN8A Mutation.
DOI:10.1210/jcemcr/luaf239 -
Blum D. 2025 Aug 18;Additional ScholarshipNew York Times Interview: A Common Weight Loss Drug Can Treat Severe Liver Disease, F.D.A. Says
-
Splete H. 2025 Aug 12;Additional ScholarshipMedscape Interview: Implantable Device Shows Promise for Preventing Hypoglycemia
-
Kraftson A. 2025 Aug 18;PresentationGLP-1 Agonists in Gastroenterology: A Double-Edged Sword
Featured News & Stories
Medical School News
2025 Dean’s Lecturer: GLP-1 therapies saving, improving lives of many patients
Lives are being saved, and many others are being changed dramatically, by current GLP-1 therapies like tirzepatide, which has helped many patients treat type 2 diabetes and sleep apnea, and also lose weight. It has been a long road from bench research to clinical trials to the health care market, but patients are now benefitting more than ever, according to a leading scientist who served as the keynote speaker for the second annual Dean’s Lecture and Bold Science Symposium, “Metabolism Research from Bench to Bedside.” Daniel Skovronsky, M.D., Ph.D., chief scientific officer and executive vice president of science and technology at Eli Lilly and Company and president of Research Laboratories and Lilly Immunology, was the Dean’s Lecturer on April 14 at the North Campus Research Complex Dining Hall.
News Release
Michigan Medicine to host live q&a discussion with obesity treatment experts
University of Michigan Health experts to discuss medications such as Wegovy, Ozempic, Zepbound and more
